Impact of Medical Castration on Malignant Arrhythmias in Patients With Prostate Cancer

• Published in: Journal of the American Heart Association 2021-03, Vol.10 (5), p.e017267-e017267
• Main Authors: Hasegawa, Kanae, Ito, Hideaki, Kaseno, Kenichi, Miyazaki, Shinsuke, Shiomi, Yuichiro, Tama, Naoto, Ikeda, Hiroyuki, Ishida, Kentaro, Uzui, Hiroyasu, Ohno, Seiko, Horie, Minoru, Yokoyama, Osamu, Tada, Hiroshi
• Format: Article
• Language: English
• Subjects: medical castration; Original Research; prostate cancer; QT prolongation; torsade de pointes; ventricular fibrillation
• ISSN: 2047-9980; 2047-9980
• DOI: 10.1161/JAHA.120.017267

Background Medical castration, gonadotropin-releasing hormone agonists, and antiandrogens have been widely applied as a treatment for prostate cancer. Sex steroid hormones influence cardiac ion channels. However, few studies have examined the proarrhythmic properties of medical castration. Methods and Results This study included 149 patients who underwent medical castration using gonadotropin-releasing hormones with/without antiandrogen for prostate cancer. The changes in the ECG findings during the therapy and associations of the electrocardiographic findings with malignant arrhythmias were studied. The QT and corrected QT (QTc) intervals prolonged during the therapy compared with baseline (QT, 394±32 to 406±39 ms [ 50 ms was 11%, and an increase in the QTc interval from the pretreatment value >80 ms was found in only 4 (3%) patients. Conclusions Medical castration prolongs the QT/QTc intervals in most patients with prostate cancer, and it could cause TdP/VFs even in patients with no risk of QT prolongation before the therapy. An increase in the QTc interval from the pretreatment value >50 ms might become a predictor of TdP/VF. Much attention should be paid to the QTc interval throughout all periods of medical castration to prevent malignant arrhythmias.